Novo Nordisk: safety profile of Tresiba strengthened.
(CercleFinance.com) - Novo Nordisk's Tresiba demonstrated no increased risk of major cardiovascular events and a significant reduction in rates of severe hypoglycaemia compared to insulin glargine, the Danish drugmaker said on Tuesday.
In a randomised trial comparing Tresiba and insulin glargine U100 in adults with type-2 diabetes at high risk of cardiovascular disease, the product met the primary endpoint of non-inferiority for major adverse cardiovascular events.
Results from the trial, involving 7,637 people with type-2 diabetes who were followed for approximately two years, were presented at the American Diabetes Association's sessions in San Diego.
At the meeting, Novo Nordisk also presented findings showing that another drug belonging to its portfolio, Victoza, reduced cardiovascular risk in people with type-2 diabetes regardless of severe hypoglycaemia events.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In a randomised trial comparing Tresiba and insulin glargine U100 in adults with type-2 diabetes at high risk of cardiovascular disease, the product met the primary endpoint of non-inferiority for major adverse cardiovascular events.
Results from the trial, involving 7,637 people with type-2 diabetes who were followed for approximately two years, were presented at the American Diabetes Association's sessions in San Diego.
At the meeting, Novo Nordisk also presented findings showing that another drug belonging to its portfolio, Victoza, reduced cardiovascular risk in people with type-2 diabetes regardless of severe hypoglycaemia events.
Copyright (c) 2017 CercleFinance.com. All rights reserved.